25113
document
Performance of a modified starch hydrophilic matrix for the sustained release of theophylline in healthy volunteers . Two experimental formulations of theophylline with a hydrophilic starch matrix were evaluated for their sustained-release characteristics after single administration in healthy human volunteers . Theo-dur was chosen as a reference sustained-release formulation . In a first study , the extent of absorption was similar for a syrup , for Theo-dur , and for the experimental formulation of theophylline with 70 % drum-dried corn starch as the sustained-release agent ( DDCS-70 ) . The maximal plasma concentration ( Cmax ) was significantly lower , and the time to reach Cmax as well as the time span during which the plasma concentration was at least 75 % of the Cmax were significantly higher for Theo-dur than for the DDCS-70 formulation . A sustained-release profile , as for Theo-dur , was not reached for DDCS-70 . In a second study the influence of the starch : drug ratio on the bioavailability was investigated . The decrease in starch content from 70 to 50 % of the formulation did not improve the plasma concentration-time profile towards a sustained-release profile .
25114
Intervention_Pharmacological
theophylline
25115
Intervention_Pharmacological
theophylline with a hydrophilic starch matrix
25116
Intervention_Pharmacological
Theo-dur
25117
Intervention_Pharmacological
Theo-dur
25118
Intervention_Pharmacological
theophylline with 70 % drum-dried corn starch as the sustained-release agent ( DDCS-70 )
25119
Intervention_Pharmacological
Theo-dur
25120
Outcome_Other
maximal plasma concentration ( Cmax )
25121
Outcome_Other
time to reach Cmax
25122
Outcome_Other
plasma concentration
25123
Outcome_Other
plasma concentration-time
25124
Participant_Condition
healthy volunteers .